|
|
|
|
A more recent version of this article appeared on April 1, 2006
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on June 21, 2005
Revised on January 18, 2006
Accepted on January 20, 2006

*Department of Biochemistry and Molecular Biology,
Marlene and Stewart Greenebaum Cancer Center, and
Center for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore, MD 21201
Monitoring Editor: Martin A. Schwartz
Tissue transglutaminase (tTG) is a multifunctional protein which serves as cross-linking enzyme and integrin-binding adhesion coreceptor for fibronectin on the cell surface. Previous work showed activation of small GTPase RhoA via enzymatic transamidation by cytoplasmic tTG. Here, we report an alternative nonenzymatic mechanism of RhoA activation by cell surface tTG. Direct engagement of surface tTG with specific antibody or the fibronectin fragment containing modules I6II1,2I7-9 increases RhoA-GTP levels. Integrin-dependent signaling to RhoA and its downstream target ROCK is amplified by surface tTG. tTG expression on the cell surface elevates RhoA-GTP levels in nonadherent and adherent cells, delays maximal RhoA activation upon cell adhesion to fibronectin and accelerates a rise in RhoA activity after binding soluble integrin ligands. These data indicate that surface tTG induces integrin clustering regardless of integrin-ligand interactions. This notion is supported by visualization of integrin clusters, increased susceptibility of integrins to chemical cross-linking and biochemical detection of large integrin complexes in cells expressing tTG. In turn, integrin aggregation by surface tTG inhibits Src kinase activity and decreases activation of the Src substrate, p190RhoGAP. Moreover, pharmacological inhibition of Src kinase reveals inactivation of Src signaling as primary cause of elevated RhoA activity in cells expressing tTG. Together, these findings show that surface tTG amplifies integrin-mediated signaling to RhoA/ROCK via integrin clustering and down-regulation of the Src-p190RhoGAP regulatory pathway.
Present address: Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205.
Address correspondence to:
Alexey M. Belkin (abelk001{at}umaryland.edu)
This article has been cited by other articles:
![]() |
K. A. Johnson, D. M. Rose, and R. A. Terkeltaub Factor XIIIA mobilizes transglutaminase 2 to induce chondrocyte hypertrophic differentiation J. Cell Sci., July 1, 2008; 121(13): 2256 - 2264. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Jiao, S. Katiyar, M. Liu, S. C. Mueller, M. P. Lisanti, A. Li, T. G. Pestell, K. Wu, X. Ju, Z. Li, et al. Disruption of c-Jun Reduces Cellular Migration and Invasion through Inhibition of c-Src and Hyperactivation of ROCK II Kinase Mol. Biol. Cell, April 1, 2008; 19(4): 1378 - 1390. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. VanBavel and E. N.T.P. Bakker A Vascular Bone Collector: Arterial Calcification Requires Tissue-Type Transglutaminase Circ. Res., March 14, 2008; 102(5): 507 - 509. [Full Text] [PDF] |
||||
![]() |
K. A. Johnson, M. Polewski, and R. A. Terkeltaub Transglutaminase 2 Is Central to Induction of the Arterial Calcification Program by Smooth Muscle Cells Circ. Res., March 14, 2008; 102(5): 529 - 537. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Im and A. Kazlauskas Src Family Kinases Promote Vessel Stability by Antagonizing the Rho/ROCK Pathway J. Biol. Chem., October 5, 2007; 282(40): 29122 - 29129. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. A. Zemskov, I. Mikhailenko, D. K. Strickland, and A. M. Belkin Cell-surface transglutaminase undergoes internalization and lysosomal degradation: an essential role for LRP1 J. Cell Sci., September 15, 2007; 120(18): 3188 - 3199. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Kudo, A. Kato, and S. Hirose Fluorescence Visualization of Branchial Collagen Columns Embraced by Pillar Cells J. Histochem. Cytochem., January 1, 2007; 55(1): 57 - 62. [Abstract] [Full Text] [PDF] |
||||